Business
Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting
-- HAV remained patent and host-cell remodeling was observed in non-human primate model -- -- Preclinical study represents milestone in the development of
About this update from Humacyte, Inc.
[{"type":"text","content":"-- HAV remained patent and host-cell remodeling was observed in non-human primate model -- -- Preclinical study represents milestone in the development of small-diameter HAVs for use in cardiac bypass surgery -- -- Results presented at Advanced Therapies Week 2022 -- DURHAM, N.C., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced results from the first preclinical study of the use of Humacyte’s small-diameter (3.5mm) Human Acellular Vessel (HAV) in coronary artery bypass grafting (CABG), which were presented at Advanced Therapies Week. The HAV maintained patency and exhibited host-cell remodeling and regeneration in a non-human primate model. CABG, performed approximately 400,000 times each year in the U.S., is a surgical procedure where a vascular graft is placed to bypass occluded coronary arteries and restore blood flow to the heart. Saphenous vein grafts are used in 80-90% of CABG procedures but have shown a 30% failure rate at one year. In the preclinical study, the 3.5mm HAVs were implanted into primates following ligation of the native right coronary artery, and the primates were studied for six months. The HAVs that have been examined to date, one being explanted at six months, remained patent and vascular host-cell repopulation was observed. The preclinical surgeries were performed by Alan P. Kypson, M.D., cardiothoracic surgeon, University of North Carolina Rex Hospital, and Adam Williams, M.D., cardiothoracic surgeon, Duke University, in collaboration with Duke’s Division of Laboratory Animal Resources and Department of Surgery. “Coronary artery bypass grafting is one of the most common surgical procedures in the U.S., but it currently requires surgically harvesting a saphenous vein for grafting. The quality and availability of the venous conduit is a critically important factor in a successful CABG and the potential to eliminate vein harvesting with a universally implantable, readily available acellular vessel is exciting,” said Dr. Kypson, who presented the results today. “Results observed in this preclinical study indicated the small-diameter HAV was an effective replacement vessel for CABG surgery in baboons, a primate that is phylogenically similar to hu...